Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 2021 January

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 04, 2021 9:44am

250 Views

Post# 32214293

RE:RE:RE:2021 January

Forestview wrote: IrishCanuck, your analysis makes sense, but it looks like you're still working on with the 38 mil share count. Would the amalgamation of Antibe Holding, which we know is happening at some point, not bump the share count to about 50 mil (Mugs, I think you mentioned a 12 mil share dilution). Am I wrong on this?

Until we know more, I have been using 50M as my fully diluted share count for most of 2020. Might even use 55M as a safer number. IMO

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"